Literature DB >> 12015776

High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum.

Maria Planck1, Eva Rambech, Gabriela Möslein, Wolfram Müller, Håkan Olsson, Mef Nilbert.   

Abstract

BACKGROUND: Patients with the familial syndrome hereditary nonpolyposis colorectal carcinoma (HNPCC) exhibit an increased risk for several tumor types, of which the greatest lifetime risk is for colorectal and endometrial carcinoma. HNPCC is caused by a germline mutation in one of several identified mismatch repair (MMR) genes and typically presents with microsatellite instability (MSI) and frequent loss of MMR protein expression in the tumor tissue. The objective of this study was to estimate the proportion of double primary tumors of the endometrium and colorectum that displays tumor characteristics suggestive of MMR deficiency.
METHODS: The authors used the southern Sweden regional population-based Cancer Registry to identify women who developed double primary tumors of the endometrium and colorectum. Of the 256 women who were diagnosed with carcinoma at both of these sites during the period 1958-1998, 39 women had developed their first tumor before age 50 years. The authors successfully retrieved 67 tumors from 36 of these patients and analyzed them for MSI and immunohistochemical expression of the MMR genes, MLH1, MSH2, and MSH6.
RESULTS: The MSI status of the 67 tumors was high MSI in 37 tumors, low MSI in 13 tumors, and microsatellite stable (MSS) in 17 tumors. Immunohistochemical loss of MMR protein expression was correlated with MSI status and was demonstrated in 29 high MSI tumors, in 1 low MSI tumor, and in 1 MSS tumor. A concordant loss of the same MMR protein in both tumors was found in 12 of 27 patients.
CONCLUSIONS: The authors demonstrated a high frequency of MSI (75%) in tumors from women with endometrial and colorectal carcinoma who had their first tumor diagnosed before age 50 years and observed concordant immunohistochemical loss of MMR protein expression, suggestive of a possible underlying germline mutation, in 12 of 27 patients (44%). They concluded that double primary malignancies of the colorectum and endometrium at a young age should make the clinician suspect HNPCC. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10501

Entities:  

Mesh:

Year:  2002        PMID: 12015776     DOI: 10.1002/cncr.10501

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Germline Variants Impact Somatic Events during Tumorigenesis.

Authors:  Johnny R Ramroop; Madelyn M Gerber; Amanda Ewart Toland
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

2.  Does the occurrence of certain rare cancers indicate an inherited cancer susceptibility?

Authors:  Sara Levene; Gillian Scott; Patricia Price; Jeremy Sanderson; Helen Evans; Claire Taylor; Sylvia Bass; Cathryn Lewis; Shirley Hodgson
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

3.  Synchronous endometrial and ovarian cancer in Lynch syndrome with a MSH2 germline mutation: A case report.

Authors:  Takashi Takeda; Kouji Banno; Megumi Yanokura; Mayuka Anko; Arata Kobayashi; Asako Sera; Takayuki Takahashi; Masataka Adachi; Yusuke Kobayashi; Shigenori Hayashi; Hiroyuki Nomura; Akira Hirasawa; Eiichiro Tominaga; Daisuke Aoki
Journal:  Mol Clin Oncol       Date:  2018-09-17

Review 4.  The Role of Immunohistochemistry Markers in Endometrial Cancer with Mismatch Repair Deficiency: A Systematic Review.

Authors:  Amelia Favier; Justine Varinot; Catherine Uzan; Alex Duval; Isabelle Brocheriou; Geoffroy Canlorbe
Journal:  Cancers (Basel)       Date:  2022-08-03       Impact factor: 6.575

5.  Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation.

Authors:  Chris Stinton; Mary Jordan; Hannah Fraser; Peter Auguste; Rachel Court; Lena Al-Khudairy; Jason Madan; Dimitris Grammatopoulos; Sian Taylor-Phillips
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.